{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:30:06Z","timestamp":1788485406910,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program","award":["2017BT01S131"],"award-info":[{"award-number":["2017BT01S131"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82022007"],"award-info":[{"award-number":["82022007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170611"],"award-info":[{"award-number":["82170611"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Outstanding Youth Development Scheme of Nanfang Hospital, Southern Medical University","award":["2020J003"],"award-info":[{"award-number":["2020J003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      A major barrier to achieving a favorable outcome of chronic HBV infection is a dysregulated HBV-specific immune response resulting from immunosuppressive features of FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      T cells. A better definition of FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      T cells is essential for improving the prognosis of HBV infection. We aimed to investigate the role of CD4\n                      <jats:sup>+<\/jats:sup>\n                      CXCR5\n                      <jats:sup>\u2212<\/jats:sup>\n                      FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      T cells with CTLA4 expression in patients with chronic HBV infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Treatment-na\u00efve chronic HBV-infected patients, HBV-related hepatic failure, and a longitudinal cohort of chronic hepatitis B (CHB) patients with nucleos(t)ide analogue treatment were enrolled for analysis of CD4\n                      <jats:sup>+<\/jats:sup>\n                      CXCR5\n                      <jats:sup>\u2212<\/jats:sup>\n                      FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      T cell responses by flow cytometry and single-cell RNA sequencing (scRNA-seq).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      ScRNA-seq revealed that circulating CD4\n                      <jats:sup>+<\/jats:sup>\n                      CXCR5\n                      <jats:sup>\u2212<\/jats:sup>\n                      FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      T cells presented distinct inhibitory features compared to spleen tissue. Meanwhile, patients with treatment-na\u00efve chronic HBV infection or with HBV-related hepatic failure showed an upregulation of immune-suppressive features (PD-1, CTLA4, GITR) on CD4\n                      <jats:sup>+<\/jats:sup>\n                      CXCR5\n                      <jats:sup>\u2212<\/jats:sup>\n                      FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      T cells; in vitro analysis found HBeAg and HBcAg stimulation induced elevated levels of inhibitory molecules. Notably, the frequency of CTLA4\n                      <jats:sup>+<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      CXCR5\n                      <jats:sup>\u2212<\/jats:sup>\n                      FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      T cells was positively correlated with HBV DNA levels, and longitudinal analysis demonstrated a high frequency of this subset at 12\u00a0weeks of antiviral treatment predicted unfavorable outcome in CHB patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      CTLA4\n                      <jats:sup>+<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      CXCR5\n                      <jats:sup>\u2212<\/jats:sup>\n                      FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      T cells are related to unfavorable outcomes in HBV-infected patients; these data indicated that alleviating CTLA4\n                      <jats:sup>+<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      CXCR5\n                      <jats:sup>\u2212<\/jats:sup>\n                      FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      T cells may improve the prognosis of HBV infection.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12865-022-00537-w","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T06:12:25Z","timestamp":1673503945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["CTLA4+CD4+CXCR5\u2212FOXP3+ T cells associate with unfavorable outcome in patients with chronic HBV infection"],"prefix":"10.1186","volume":"24","author":[{"given":"Chunhua","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"issue":"1","key":"537_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","volume":"22","author":"M Iannacone","year":"2022","unstructured":"Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol. 2022;22(1):19\u201332.","journal-title":"Nat Rev Immunol"},{"key":"537_CR2","doi-asserted-by":"publisher","first-page":"m2200","DOI":"10.1136\/bmj.m2200","volume":"370","author":"Y Shi","year":"2020","unstructured":"Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. BMJ. 2020;370:m2200.","journal-title":"BMJ"},{"issue":"11","key":"537_CR3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","volume":"18","author":"GC Fanning","year":"2019","unstructured":"Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18(11):827\u201344.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"537_CR4","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","volume":"67","author":"T Berg","year":"2017","unstructured":"Berg T, Simon KG, Mauss S, Schott E, Heyne R, Klass DM, Eisenbach C, Welzel TM, Zachoval R, Felten G, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients\u2014FINITE study. J Hepatol. 2017;67(5):918\u201324.","journal-title":"J Hepatol"},{"issue":"10161","key":"537_CR5","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","volume":"392","author":"WK Seto","year":"2018","unstructured":"Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet. 2018;392(10161):2313\u201324.","journal-title":"Lancet"},{"issue":"8","key":"537_CR6","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1053\/j.gastro.2018.03.021","volume":"154","author":"X Wang","year":"2018","unstructured":"Wang X, Dong Q, Li Q, Li Y, Zhao D, Sun J, Fu J, Meng F, Lin H, Luan J, et al. Dysregulated response of follicular helper T cells to hepatitis B surface antigen promotes HBV persistence in mice and associates with outcomes of patients. Gastroenterology. 2018;154(8):2222\u201336.","journal-title":"Gastroenterology"},{"issue":"11","key":"537_CR7","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nri.2017.75","volume":"17","author":"L Lu","year":"2017","unstructured":"Lu L, Barbi J, Pan F. The regulation of immune tolerance by FOXP3. Nat Rev Immunol. 2017;17(11):703\u201317.","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"537_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","volume":"8","author":"DA Vignali","year":"2008","unstructured":"Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523\u201332.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"537_CR9","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ni.2868","volume":"15","author":"A Arvey","year":"2014","unstructured":"Arvey A, van der Veeken J, Samstein RM, Feng Y, Stamatoyannopoulos JA, Rudensky AY. Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells. Nat Immunol. 2014;15(6):580\u20137.","journal-title":"Nat Immunol"},{"issue":"1","key":"537_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41467-018-08123-8","volume":"10","author":"S Chen","year":"2019","unstructured":"Chen S, Fan J, Zhang M, Qin L, Dominguez D, Long A, Wang G, Ma R, Li H, Zhang Y, et al. CD73 expression on effector T cells sustained by TGF-beta facilitates tumor resistance to anti-4-1BB\/CD137 therapy. Nat Commun. 2019;10(1):150.","journal-title":"Nat Commun"},{"issue":"27","key":"537_CR11","doi-asserted-by":"publisher","first-page":"4310","DOI":"10.3748\/wjg.v12.i27.4310","volume":"12","author":"Y Kondo","year":"2006","unstructured":"Kondo Y, Kobayashi K, Ueno Y, Shiina M, Niitsuma H, Kanno N, Kobayashi T, Shimosegawa T. Mechanism of T cell hyporesponsiveness to HBcAg is associated with regulatory T cells in chronic hepatitis B. World J Gastroenterol. 2006;12(27):4310\u20137.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"537_CR12","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/nm.2002","volume":"15","author":"M Feuerer","year":"2009","unstructured":"Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, Lee J, Goldfine AB, Benoist C, Shoelson S, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009;15(8):930\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"537_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00798.x","volume":"230","author":"DK Hsu","year":"2009","unstructured":"Hsu DK, Chen HY, Liu FT. Galectin-3 regulates T-cell functions. Immunol Rev. 2009;230(1):114\u201327.","journal-title":"Immunol Rev"},{"issue":"11","key":"537_CR14","doi-asserted-by":"publisher","first-page":"6572","DOI":"10.1093\/nar\/gkx441","volume":"45","author":"MD Ilsley","year":"2017","unstructured":"Ilsley MD, Gillinder KR, Magor GW, Huang S, Bailey TL, Crossley M, Perkins AC. Kr\u00fcppel-like factors compete for promoters and enhancers to fine-tune transcription. Nucleic Acids Res. 2017;45(11):6572\u201388.","journal-title":"Nucleic Acids Res"},{"key":"537_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2019.101010","volume":"76","author":"RC Gilson","year":"2019","unstructured":"Gilson RC, Gunasinghe SD, Johannes L, Gaus K. Galectin-3 modulation of T-cell activation: mechanisms of membrane remodelling. Prog Lipid Res. 2019;76:101010.","journal-title":"Prog Lipid Res"},{"key":"537_CR16","doi-asserted-by":"crossref","unstructured":"He Y, Luo J, Zhang G, Jin Y, Wang N, Lu J, Li C, Guo X, Qin N, Dai J, et al. Single-cell profiling of human CD127(+) innate lymphoid cells reveals diverse immune phenotypes in hepatocellular carcinoma. Hepatology. 2022;76(4):1013\u201329.","DOI":"10.1002\/hep.32444"},{"issue":"10161","key":"537_CR17","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","volume":"392","author":"W-K Seto","year":"2018","unstructured":"Seto W-K, Lo Y-R, Pawlotsky J-M, Yuen M-F. Chronic hepatitis B virus infection. Lancet. 2018;392(10161):2313\u201324.","journal-title":"Lancet"},{"key":"537_CR18","doi-asserted-by":"crossref","unstructured":"Zhang C, Li J, Cheng Y, Meng F, Song JW, Fan X, Fan H, Li J, Fu YL, Zhou MJ, et al. Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients. Gut. 2023;72(1):153\u201367.","DOI":"10.1136\/gutjnl-2021-325915"},{"issue":"2","key":"537_CR19","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1053\/j.gastro.2020.04.019","volume":"159","author":"N Le Bert","year":"2020","unstructured":"Le Bert N, Gill US, Hong M, Kunasegaran K, Tan DZM, Ahmad R, Cheng Y, Dutertre CA, Heinecke A, Rivino L, et al. Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection. Gastroenterology. 2020;159(2):652\u201364.","journal-title":"Gastroenterology"},{"issue":"3","key":"537_CR20","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/hep.25765","volume":"56","author":"L Stross","year":"2012","unstructured":"Stross L, G\u00fcnther J, Gasteiger G, Asen T, Graf S, Aichler M, Esposito I, Busch DH, Knolle P, Sparwasser T, et al. Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice. Hepatology. 2012;56(3):873\u201383.","journal-title":"Hepatology"},{"issue":"4","key":"537_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jhep.2011.10.020","volume":"56","author":"SW Ma","year":"2012","unstructured":"Ma SW, Huang X, Li YY, Tang LB, Sun XF, Jiang XT, Zhang YX, Sun J, Liu ZH, Abbott WG, et al. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. J Hepatol. 2012;56(4):775\u201381.","journal-title":"J Hepatol"},{"issue":"4","key":"537_CR22","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/hep.26489","volume":"58","author":"Y Li","year":"2013","unstructured":"Li Y, Ma S, Tang L, Li Y, Wang W, Huang X, Lai Q, Zhang M, Sun J, Li CK, et al. Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+) T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection. Hepatology. 2013;58(4):1277\u201386.","journal-title":"Hepatology"},{"issue":"2","key":"537_CR23","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"EASL 2017","year":"2017","unstructured":"EASL 2017. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","journal-title":"J Hepatol"},{"issue":"3","key":"537_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jhep.2019.09.031","volume":"72","author":"Y Li","year":"2020","unstructured":"Li Y, Tang L, Guo L, Chen C, Gu S, Zhou Y, Ye G, Li X, Wang W, Liao X, et al. CXCL13-mediated recruitment of intrahepatic CXCR5(+)CD8(+) T cells favors viral control in chronic HBV infection. J Hepatol. 2020;72(3):420\u201330.","journal-title":"J Hepatol"},{"issue":"1","key":"537_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/hep.29155","volume":"66","author":"AD Kosinska","year":"2017","unstructured":"Kosinska AD, Pishraft-Sabet L, Wu W, Fang Z, Lenart M, Chen J, Dietze KK, Wang C, Kemper T, Lin Y, et al. Low hepatitis B virus-specific T-cell response in males correlates with high regulatory T-cell numbers in murine models. Hepatology. 2017;66(1):69\u201383.","journal-title":"Hepatology"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-022-00537-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-022-00537-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-022-00537-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T06:15:39Z","timestamp":1673504139000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-022-00537-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["537"],"URL":"https:\/\/doi.org\/10.1186\/s12865-022-00537-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1812497\/v1","asserted-by":"object"}]},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,12]]},"assertion":[{"value":"30 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethical Committee of Nanfang Hospital, and all subjects provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}